تقرير
Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer
| العنوان: | Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer |
|---|---|
| المساهمون: | David Patrick Ryan, MD, Principal Investigator |
| المصدر: | Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer |
| الوصول الحر: | https://clinicaltrials.gov/ct2/show/NCT02243007Test |
| قاعدة البيانات: | ClinicalTrials.gov |
| ResultId |
1 |
|---|---|
| Header |
edsclt ClinicalTrials.gov edsclt.NCT02243007 810 2 Report report 810 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsclt&AN=edsclt.NCT02243007&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://clinicaltrials.gov/ct2/show/NCT02243007# [Name] => EDS – ClinicalTrials.gov [Category] => fullText [Text] => View record in ClinicalTrials.gov [MouseOverText] => View record in ClinicalTrials.gov ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer
)
Array ( [Name] => Author [Label] => Contributors [Group] => Au [Data] => David Patrick Ryan, MD, Principal Investigator ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer ) Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://clinicaltrials.gov/ct2/show/NCT02243007" linkWindow="_blank">https://clinicaltrials.gov/ct2/show/NCT02243007</link> ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Languages] => Array
(
[0] => Array
(
[Text] => English
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => David Patrick Ryan, MD, Principal Investigator
)
)
)
)
)
)
|
| IllustrationInfo |